Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects

JAMA

Volumn 304, Issue 8, 2010, Pages 859-866

  Pasternak, Björn ^a   Hviid, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; VALACICLOVIR; 2 AMINOPURINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; VALINE;

ADULT; ARTICLE; BIRTH DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; FEMALE; FIRST TRIMESTER PREGNANCY; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFANT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; ADOLESCENT; CONGENITAL MALFORMATION; MIDDLE AGED; PREGNANCY; RETROSPECTIVE STUDY; RISK;

2-AMINOPURINE; ABNORMALITIES, DRUG-INDUCED; ACYCLOVIR; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DENMARK; FEMALE; HERPES SIMPLEX; HERPES ZOSTER; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RETROSPECTIVE STUDIES; RISK; VALINE; YOUNG ADULT;

EID: 77955933856     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1206     Document Type: Article

References (29)

1. Sen P, Barton SE. Genital herpes and its management. BMJ. 2007;334(7602):1048-1052.
2. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med. 2008;168(11):1137-1144. (Pubitemid 351831395)
3. Wareham DW, Breuer J. Herpes zoster. BMJ. 2007;334(7605):1211-1215.
4. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis. 2002;186(suppl 1):S3-S28. (Pubitemid 35178845)
5. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964-973. (Pubitemid 44285373)
6. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994;121(11):847-854.
7. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl JMed. 1997;337(8):509-515. (Pubitemid 27352016)
8. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349. (Pubitemid 350060129)
9. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experiencewith acyclovir. J Infect Dis. 2002;186(suppl 1):S40-S46. (Pubitemid 35178848)
10. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 1994;38(10):2454-2457. (Pubitemid 24304247)
11. Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 1 teratology. Obstet Gynecol. 2009;113(1):166-188.
12. Moore HL Jr, Szczech GM, Rodwell DE, Kapp RW Jr, de Miranda P, Tucker WE Jr. Preclinical toxicology studies with acyclovir: teratologic, reproductive and neonatal tests. Fundam Appl Toxicol. 1983;3(6):560-568. (Pubitemid 14199847)
13. Chahoud I, Stahlmann R, Bochert G, Dillmann I, Neubert D. Gross-structural defects in rats after acyclovir application on day 10 of gestation. Arch Toxicol. 1988;62(1):8-14.
14. US Food and Drug Administration. Zovirax (acyclovir product information), GlaxoSmithKline, 2005. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2005/018828s030,020089s019,019909s020lbl.pdf. Accessed July 5, 2010.
15. US Food and Drug Administration. Valtrex (valacyclovir product information), GlaxoSmithKline, 2008. http://www.accessdata.fda.gov/drugsatfda- docs/label/2010/020487s016lbl.pdf. Accessed July 5, 2010.
16. US Food and Drug Administration. Famvir (famciclovir product information), Novartis, 2009. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2009/020363s036lbl.pdf. Accessed July 5, 2010.
17. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol. 2004;70(4):201-207.
18. Ratanajamit C, Vinther Skriver M, et al. Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study. Scand J Infect Dis. 2003;35(4):255-259. (Pubitemid 36806035)
19. Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol. 1998;105(8):882-889.
20. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull. 1998;45(3):320-323.
21. Jørgensen FS. Ultrasonography of pregnant women in Denmark 1999-2000: description of the development since 1980-1990. Ugeskr Laeger. 2003;165(46):4409-4415.
22. Kristensen J, Langhoff-Roos J, Skovgaard LT, Kristensen FB. Validation of the Danish Birth Registration. J Clin Epidemiol. 1996;49(8):893-897.
23. Danmarks Statistik. Research databases: data sources available at Statistics Denmark [in Danish] (ISBN 8701-501-1301-1). http://www.dst.dk/upload/ forskningsdatabaser.pdf. Accessed August 2, 2010.
24. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263-268. (Pubitemid 29299976)
25. Eurocat Network. Chapter 3.3: coding of Eurocat subgroups of congenital anomalies, issued on January, 03, 2007. http://www.eurocat-network.eu/content/ EUROCAT-Guide-1.3.pdf. Accessed March 3, 2010.
26. Eurocat Network. Chapter 3.2: minor anomalies for exclusion, issued on 31-08-2007. http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf. Accessed March 3, 2010.
27. Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB. The Danish Civil Registration System: a cohort of eight million persons. Dan Med Bull. 2006;53(4):441-449.
28. Larsen H, Nielsen GL, Bendsen J, Flint C, Olsen J, Sørensen HT. Predictive value and completeness of the registration of congenital abnormalities in three Danish population-based registries. Scand J Public Health. 2003;31(1):12-16.
29. Jepsen B, Jepsen P, Johnsen SP, Espersen GT, Sørensen HT. Validity of diagnoses of cardiac malformations in a Danish population-based hospital-discharge registry. Int J Risk Saf Med. 2006;18(2):77-81.